Letter

So much time for so little: Italy's pharmaceutical industry and doctors' information needs

BMJ 2000; 320 doi: 10.1136/bmj.320.7226.55 (Published 1 January 2000)
Cite this as: BMJ 2000;320:55

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Emilio Maestri, general practitioner,
  2. Gilberto Furlani, general practitioner,
  3. Fabio Suzzi, general practitioner,
  4. Annalisa Campomori, pharmacist,
  5. Giulio Formoso, epidemiologist,
  6. Nicola Magrini, head (n.magrini@ausl.mo.it)
  1. Guastalla, Reggio Emilia, Italy
  2. Imola, Bologna, Italy
  3. Unit of Drug Evaluation and Evidence-Based Primary Care, Centro per la Valutazione della Efficacia della Assistenza Sanitaria (CeVEAS), 41100 Modena, Italy

    EDITOR—Two local experiences in northern Italy may be relevant to the discussion following the recent editorial by Griffith on doctors' reasons for not seeing drug representatives.1

    In 1992, eight general practitioners from Guastallae evaluated the amount of time spent with pharmaceutical representatives. On average, each doctor had 435 visits per year from 102 different companies and spent a total of 58 hours every year talking to pharmaceutical representatives. To reduce this time, four doctors allowed up to two visits per day, and …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular